RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

Benzinga · 6d ago
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.